Patient perspectives on the use of oral corticosteroids in asthma

被引:0
|
作者
Winders, Tonya [1 ]
Fletcher, Monica [2 ]
Oppenheimer, John [3 ]
Howarth, Peter [4 ]
Antoun, Zeina Eid [5 ]
van der Molen, Thys [6 ]
Heaney, Liam G. [7 ]
Thomas, Mike [8 ]
机构
[1] Global Allergy & Airways Patient Platform, 10 Altgasse, A-1130 Vienna, Austria
[2] Univ Edinburgh, Edinburgh, Scotland
[3] Pulm & Allergy Associates, Bridgewater, NJ USA
[4] GSK, London, England
[5] ViiV Healthcare, London, Middx, England
[6] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD GRIAC, Groningen, Netherlands
[7] Queens Univ, Belfast, North Ireland
[8] Univ Southampton, Southampton, England
关键词
Asthma; oral corticosteroids; patients' perspective; medication adherence; education; patient-provider communication; ADVERSE EVENTS; PERCEPTIONS; MEPOLIZUMAB;
D O I
10.1080/02770903.2025.2466183
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
ObjectiveOral corticosteroids (OCS) are used to treat uncontrolled asthma, either as short rescue courses of treatment for severe disease exacerbations, or as long-term maintenance therapy in addition to other controller medications. Although the adverse events (AEs) associated with OCS are well understood by healthcare professionals (HCPs), the patient's perspective may be underappreciated. This review discusses the patient perspective on OCS use.Data SourcesA PubMed literature review was performed.Study SelectionArticles were selected to include those primarily containing data on patient perspectives on OCS use in asthma or other airway diseases, including qualitative and quantitative studies. Articles including only clinical data and those primarily focused on another indication were excluded. Additional articles meeting the criteria were permitted based on author knowledge and the bibliographies of systematic reviews on other topics.ResultsA total of 6066 articles were identified from the PubMed search; 111 were assessed more closely for eligibility. Fourteen articles were eventually selected by the reviewers for inclusion and confirmed by all authors. Several key themes were identified: (1) Key AEs were prominently reported by patients (including weight gain, skin thinning, known osteoporosis/osteopenia, and sleep/mood disturbances); (2) Impact of OCS on day-to-day lives; (3) Patient perceptions of OCS; (4) Effect of perceptions on treatment adherence.ConclusionHCPs should consider the impact that OCS have on their patients' wellbeing, including short courses. It is essential for HCPs to discuss the short and long-term risks of OCS with patients prior to initiation of treatment and consider alternatives for patients on long-term OCS.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma
    Al Efraij, Khalid
    Johnson, Kate M.
    Wiebe, Darrin
    Sadatsafavi, Mohsen
    FitzGerald, J. Mark
    JOURNAL OF ASTHMA, 2019, 56 (12) : 1334 - 1346
  • [2] Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients
    Latorre, Manuela
    Rizzi, Angela
    Paggiaro, Pierluigi
    Baiardini, Ilaria
    Bagnasco, Diego
    Del Giacco, Stefano
    Lombardi, Carlo
    Patella, Vincenzo
    Nucera, Eleonora
    Parente, Roberta
    Paoletti, Giovanni
    Pini, Laura
    Ridolo, Erminia
    Senna, Gianenrico
    Blasi, Francesco
    Canonica, Giorgio Walter
    JOURNAL OF ASTHMA, 2024, 61 (10) : 1294 - 1305
  • [3] A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma
    Haughney, John
    Winders, Tonya
    Holmes, Steve
    Chanez, Pascal
    Menzies-Gow, Andrew
    Kocks, Janwillem
    Mansur, Adel H.
    McPherson, Christopher
    Canonica, Giorgio Walter
    ADVANCES IN THERAPY, 2023, 40 (06) : 2577 - 2594
  • [4] Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry
    Graff, S.
    Vanwynsberghe, S.
    Brusselle, G.
    Hanon, S.
    Sohy, C.
    Dupont, L. J.
    Peche, R.
    Michils, A.
    Pilette, C.
    Joos, G.
    Louis, R. E.
    Schleich, F. N.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [5] Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma
    Katsaounou, Paraskevi
    Buhl, Roland
    Brusselle, Guy
    Pfister, Pascal
    Martinez, Rafael
    Wahn, Ulrich
    Bousquet, Jean
    RESPIRATORY MEDICINE, 2019, 150 : 51 - 62
  • [6] Oral corticosteroids and asthma in children: Practical considerations
    De Filippo, Maria
    Clark, Evangeline
    Fillard, Anouchka
    Diaferio, Lucia
    Caimmi, Davide
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2020, 31 : 43 - 45
  • [7] Patient experiences with maintenance oral corticosteroid use in severe asthma
    Harrington, J.
    Harvey, E.
    Stevens, S.
    Thomas, D.
    McDonald, V
    Gibson, P.
    RESPIROLOGY, 2023, 28 : 36 - 37
  • [8] Minimize systemic oral corticosteroids use and reduce harm for patients with asthma
    Ko, Fanny Wai San
    Salvi, Sundeep
    RESPIROLOGY, 2023, 28 (08) : 694 - 695
  • [9] Morbidity associated with oral corticosteroids in patients with severe asthma
    Choo, Xue Ning
    Pavord, Ian D.
    THORAX, 2016, 71 (04) : 302 - 304
  • [10] Patterns of oral corticosteroids use in primary care patients with severe asthma
    Vetrano, Davide L.
    Zucchelli, Alberto
    Bianchini, Elisa
    Marconi, Ettore
    Lombardo, Francesco P.
    Cricelli, Claudio
    Lapi, Francesco
    RESPIRATORY MEDICINE, 2020, 166